Standardization protocols and optimized precursor sets for the efficient application of automated parallel synthesis to lead optimization: A mitsunobu example

Journal of Combinatorial Chemistry

Volumn 4, Issue 5, 2002, Pages 442-456

  Gentles, Robert G ^a,b   Wodka, Dariusz ^a   Park, David C ^a   Vasudevan, Anil ^a  

^a ABBOTT LABORATORIES   (United States)

^b BRISTOL MYERS SQUIBB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE;

EID: 0037617581     PISSN: 15204766     EISSN: None     Source Type: Journal    
DOI: 10.1021/cc010090j     Document Type: Article

References (36)

1. Drews, J.; Ryser, S. Nat. Biotechnol. 1997, 15, 1318.
2. Drews, J. In Human Disease - From Genetic Causes to Biochemical Effects; Drews J.; Ryser, S., Eds.; Blackwell: Oxford, 1997; p 5.
3. Wermuth, C. G. Agressologie 1966, 7, 213.
4. Topliss, J. G. Perspect. Drug Discovery Des. 1993, 1, 253.
5. (a) Craig, P. N. Guidelines for drug and analog design. In The Basis of Medicinal Chemistry; Wolf, M. E., Ed.; Wiley-Interscience: New York, 1980; p 331.
6. (b) Austel, V. Features and problems in practical drug design. In Steric Effects in Drug Design; Charton, M., Motoc, I., Eds.; Lange and Springer: Berlin, 1984; p 8.
7. Austel, V. Experimental design. In Methods and Principles in Medicinal Chemistry; van de Waterbeemd, H., Ed.; Chemometric Methods in Molecular Design, Vol. 2; VCH: Weinheim, Germany, 1995; p 49.
8. (a) Dean, P. M.; Lewis, R. A. Molecular Diversity in Drug Design; Kluwer: Amsterdam, 1999.
9. (b) Martin, Y. C. J. Comb. Chem. 2001, 3, 231.
10. Haag, B. T. Chimia 2000, 54, 163.
11. (a) Wen, S.; Wang, S. Huaxue Shiji 2000, 22, 285.
12. (b) Ghosh, P. K.; Kumar, P.; Gupta, K. C. J. Indian Chem. Soc. 2000, 77, 109.
13. Cammish, L. E.; Kates, S. A. In Fmoc Solid Phase Peptide Synthesis: A Practical Approach; Chan, W. C., White, P. D., Eds.; Oxford University Press: Oxford, 2000; p 277.
14. Davis. A. M.; Teague, S. J. Angew. Chem., Int. Ed. 1999, 38, 736.
15. Available Chemicals Directory ACD 2000.2; MDL Information Systems, Inc., 1982-2000.
16. (a) Frierson, M. R., III. Abstr. Pap. - Am. Chem. Soc. 2001, 221st, CINF-030.
17. (b) Andrews, C. W.; Bennett, L.; Yu, L. X. Pharm. Res. 2000, 17, 639.
18. (a) Adamson, G. W.; Bush, J. A. Inf. Storage Retr. 1973, 9, 561.
19. (b) Matter, H. J. Med. Chem. 1997, 40, 1219.
20. (c) Brown, R. D.; Martin, Y. C. J. Chem. Inf. Comput. Sci. 1996, 36, 572.
21. PE Biosystems (Applied Biosystems) Solaris 530 organic synthesizer. For additional information see the following: www.appliedbiosystems.com.
22. (a) Rano, T. A.; Chapman, K. T. Tetrahedron Lett. 1995, 36, 3789.
23. (b) Krchnak, V.; Flegelova, Z.; Weichsel, A. S.; Lebl, M. Tetrahedron Lett. 1995, 36, 6193.
24. (a) Hughes, D. L. Organic Reactions; Wiley: New York, 1992; Vol. 42, p 335.
25. (b) Hughes, D. L. Org. Prep. Proced. Int. 1996, 28, 127.
26. Pelletier, J. C.; Kincaid, S. Tetrahedron Lett. 2000, 41, 797.
27. 21
28. 3 {lot number 113-81, loading 1.24 mmol/g}: the percentage of phosphine oxide increased from 23% to 36% over 7 days, atmospheric exposure.
29. 4 as an external standard. The pulse delay employed was 15 s, and chemical shifts are quoted in ppm. Under these conditions, the phosphine resonance was observed at -6.25 ppm, with the oxide being observed at 29.40 ppm.
30. (a) Hughes, D. L.; Reamer, R. A.; Bergan, J. J.; Grabowski, E. J. J. J. Am. Chem. Soc. 1988, 110, 6487.
31. (b) Guthrie, R. D. G.; Jenkins, I. D. Aust. J. Chem. 1982, 35, 767.
32. Masada, H.; Yammamoto, T.; Yamamoto, F. Nippon Kagaku Kaishi 1995, 12, 1028.
33. (a) Kurihara, T.; Sugizaki, M.; Kime, I.; Wada, M.; Mitsunobu, O. Bull. Chem. Soc. Jpn. 1981, 54, 2107.
34. (b) Racero, J. C.; Macias-Sanchez, A. J.; Hernandez-Galan, R.; Hitchcock, P. B.; Hanson, J. R.; Collado, I. G. J. Org. Chem. 2000, 65, 7786.
35. (a) Sammes, P. G.; Smith, S. J. Chem. Soc., Chem. Commun. 1983, 682.
36. (b) Sammes, P. G.; Smith, S. J. Chem. Soc., Perkin Trans, 1 1985, 30, 2415.